000538:SZSEYunnan Baiyao Group Co.,Ltd Analysis

Yunnan Baiyao is trading at CNY 56.15, which sits below its 20‑day (56.38), 50‑day (56.55) and 200‑day (56.65) simple moving averages, signaling a short‑term bearish bias. The MACD line remains under its signal line and the RSI hovers at 47, confirming a lack of momentum, while volume has been on a decreasing trend, adding pressure to the price. Despite the technical weakness, the stock’s PE of 19.2 is well under the industry average of 25.1, and the forward PE of 18.2 suggests modest earnings growth ahead. However, the DCF‑derived fair value of only CNY 34.80 places the current market price far above intrinsic estimates, indicating an overvaluation from a discounted‑cash‑flow perspective. On the upside, the dividend yield of 5.84% is attractive, with a payout ratio of 40% backed by strong operating cash flow of CNY 4.68 bn, supporting dividend sustainability. The company’s beta is exceptionally low (≈0.02‑0.30), implying minimal market‑wide volatility, while 30‑day price volatility sits at 12% and the max drawdown is limited to 8%, portraying a relatively stable risk profile.
Fundamentally, Yunnan Baiyao delivers solid profitability with a 12.8% profit margin, 14.5% operating margin and a healthy ROE of 13.0%. Cash reserves of CNY 13.58 bn dwarf its modest debt of CNY 0.29 bn, resulting in a debt‑to‑equity of 0.72 and ample liquidity. The company’s diversified product mix, long heritage since 1902, and consistent dividend payments make it a resilient player in China’s specialty pharma sector, though regulatory scrutiny remains a consideration.